Oprozomib (ONX 0912)
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205565

CAS#: 935888-69-0

Description: Oprozomibm, also known as ONX 0912 and PR 047 , is a n orally bioavailable proteasome inhibitor with potential antineoplastic activity. ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.


Price and Availability

Size Price Shipping out time Quantity
10mg USD 150 Same Day
25mg USD 250 Same Day
50mg USD 450 Same Day
100mg USD 750 Same Day
200mg USD 1250 Same Day
500mg USD 1950 Same Day
1g USD 2750 2 Weeks
2g USD 3950 2 Weeks
5g USD 5950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-20. Prices are subject to change without notice.

Oprozomib, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 205565
Name: Oprozomib (ONX 0912)
CAS#: 935888-69-0
Chemical Formula: C25H32N4O7S
Exact Mass: 532.19917
Molecular Weight: 532.60918
Elemental Analysis: C, 56.38; H, 6.06; N, 10.52; O, 21.03; S, 6.02


Synonym: ONX0912; ONX-0912; ONX 0912; PR047; PR-047; PR 047.

IUPAC/Chemical Name: N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide

InChi Key: SWZXEVABPLUDIO-WSZYKNRRSA-N

InChi Code: InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1

SMILES Code: O=C(C1=CN=C(C)S1)N[C@@H](COC)C(N[C@@H](COC)C(N[C@@H](CC2=CC=CC=C2)C([C@]3(C)OC3)=O)=O)=O


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

ONX 0912 is a tripeptide epoxyketone, which inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies. The anti-MM activity of ONX-0912 is associated with activation of caspase-8, caspase-9, caspase-3, and poly(ADP) ribose polymerase, as well as inhibition of migration of MM cells and angiogenesis. ONX 0912 , like bortezomib, predominantly inhibits chymotrypsin-like activity of the proteasome and is distinct from bortezomib in its chemical structure. Importantly, ONX 0912 is orally bioactive. In animal tumor model studies, ONX 0912 significantly reduced tumor progression and prolonged survival. Immununostaining of MM tumors from ONX 0912 -treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Finally, ONX 0912 enhances anti-MM activity of bortezomib, lenalidomide dexamethasone, or pan-histone deacetylase inhibitor. Taken together, our study provides the rationale for clinical protocols evaluating ONX 0912 , either alone or in combination, to improve patient outcome in MM. (source: Blood. 2010 Dec 2;116(23):4906-15.)
 
Onyx is developing ONX 0912, a novel oral proteasome inhibitor. ONX 0912 inhibits the 20S proteasome that primarily targets chymotrypsin-like activity. ONX 0912 is distinct from carfilzomib, although the compound is based on the same chemistry that is employed to selectively target the proteasome. As an orally-dosed agent, ONX 0912 is designed to provide prolonged proteasome inhibition and combinability with other available therapies with the convenience of an oral therapy. (source: http://www.onyx-pharm.com/clinical-development/onx-091).
  
  
 


References

1. Use of peptide epoxyketone proteasome inhibitors for metastasis suppression By Kirk, Christopher J.; Jiang, Jing From PCT Int. Appl. (2011), WO 2011060179 A1 20110519.

2. Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis By Schubert, Ulrich From PCT Int. Appl. (2011), WO 2011009961 A1 20110127.

3. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma By Chauhan, Dharminder; Singh, Ajita V.; Aujay, Monette; Kirk, Christopher J.; Bandi, Madhavi; Ciccarelli, Bryan; Raje, Noopur; Richardson, Paul; Anderson, Kenneth C. From Blood (2010), 116(23), 4906-4915.

4. Preparation and thermal properties of crystalline tripeptide epoxy ketone protease inhibitors By Phiasivongsa, Pasit; Sehl, Louis C. From PCT Int. Appl. (2010), WO 2010108172 A1 20100923.

5. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia By Roccaro, Aldo M.; Sacco, Antonio; Aujay, Monette; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; et al From Blood (2010), 115(20), 4051-4060.

6. Use of quinazoline derivatives for the treatment of hematologic malignancies, inflammatory and autoimmune disorders By Gallatin, Michael W.; Ulrich, Roger G.; Giese, Neill From PCT Int. Appl. (2010), WO 2010057048 A1 20100520.

7. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy By Dick, Lawrence R.; Fleming, Paul E. From Drug Discovery Today (2010), 15(5/6), 243-249.

8. Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047) By Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; et al From Journal of Medicinal Chemistry (2009), 52(9), 3028-3038.

9. Preparation of peptide epoxides and peptide aziridines as enzyme inhibitors, especially N-terminal nucleophile hydrolase inhibitors, for treating diseases By Zhou, Han-Jie; Laidig, Guy J.; Shenk, Kevin D.; Sun, Congcong M. From PCT Int. Appl. (2008), WO 2008140782 A2 20081120.

10. Compounds for enzyme inhibition By Zhou, Han-Jie; Sun, Congcong M.; Shenk, Kevin D.; Laidig, Guy J. From U.S. Pat. Appl. Publ. (2007), US 20070105786 A1 20070510.